Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab with Radiotherapy in Advanced NSCLC
NCT03509584Phase 1Terminated
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Incidence of immune related adverse events at 48 weeks. Started Jun 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03509584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509584.